

**Drugs and Therapeutics (D & T) Committee
Meeting Results
May 9, 2018**

Drug Name	Review Type	Committee Recommendation	Prior Approval Status – Final Determination
Mitigare	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Brilinta	New Drug Appeal	Preferred, no PA	Preferred, no PA
Qvar Redihaler	New Drug Appeal	Non-preferred requires PA	Non-preferred requires PA
Aptensio XR	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Copaxone 40mg	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA